Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
AssigneeREMD Biotherapeutics, Inc.
InventorsHai Yan, Jim Shi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating type 1 diabetes (T1D) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating T1D using substantially lower doses of insulin supplementation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.
Claims12
A method of treating a patient diagnosed with type 1 diabetes (T1 D) comprising administering to the patient:
- (a) a therapeutically effective amount of an isolated human antibody that specifically binds to the human glucagon receptor and comprises:
- (i) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 4, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 5;
- (ii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 6, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 7;
- (iii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 28, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 47;
- or (iv) a heavy chain comprising amino acids having the sequence set forth in of SEQ ID NO:
- 51, and the light chain comprising amino acids having the sequence set forth in SEQ ID NO:
- 52;
- and (b) insulin supplementation, wherein the insulin supplementation comprises 90% to 0.1% of a normal daily dosage of insulin supplementation.
A method for reducing, suppressing, attenuating, or inhibiting one or more symptoms associated with T1 D, comprising administering to the patient:
- (a) a therapeutically effective amount of an isolated human antibody that specifically binds to the human glucagon receptor and comprises:
- (i) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 4, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 5;
- (ii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 6, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 7;
- (iii) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 28, and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:
- 47;
- or (iv) a heavy chain comprising amino acids having the sequence set forth in of SEQ ID NO:
- 51, and the light chain comprising amino acids having the sequence set forth in SEQ ID NO:
- 52;
- and (b) insulin supplementation, wherein the insulin supplementation comprises 90% to 1% of a normal daily dosage of insulin supplementation.
Dependencies are inferred from the claim text.